Clinical Trial: NCT05078593
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Shanghai Henlius Biotech |
| Information Provided By: | Shanghai Henlius Biotech |
| Last Update Posted: | 2024-02-23 |
Study Overview
Brief Summary
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
Official Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection (Anti LAG-3 Monoclonal Antibody) in Patients With Advanced/Metastatic Solid Tumor or Lymphoma
Conditions
Solid Tumor, Adult, Lymphoma
Intervention / Treatment
- Drug: HLX26
Other Study ID Numbers
- HLX26-001
Start Date (Actual)
2021-10-11
Primary Completion Date (Actual)
2023-08-18
Study Completion Date (Actual)
2023-08-18
Enrollment (Actual)
18
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Shanghai Henlius Biotech |
| Information Provided By: | Shanghai Henlius Biotech |
| Last Update Posted: | 2024-02-23 |
Study Overview
Brief Summary
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
Official Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection (Anti LAG-3 Monoclonal Antibody) in Patients With Advanced/Metastatic Solid Tumor or Lymphoma
Conditions
Solid Tumor, Adult, Lymphoma
Intervention / Treatment
- Drug: HLX26
Other Study ID Numbers
- HLX26-001
Start Date (Actual)
2021-10-11
Primary Completion Date (Actual)
2023-08-18
Study Completion Date (Actual)
2023-08-18
Enrollment (Actual)
18
Study Type
Interventional
Phase
Phase 1